SCHEMBL3560166

SCHEMBL3560166

Fc1cccc(Br)c1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IKBKB O14920 1/20 0.43
▸ BRD4 O60885 1/20 0.43
▸ MAOB P27338 1/20 0.43
▸ MAPT P10636 1/20 0.42
▸ CNR2 P34972 1/20 0.42
▸ ADORA1 P30542 1/20 0.42
▸ AKR1C3 P42330 1/20 0.42
▸ AKR1C2 P52895 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.41
▸ IL2 P60568 1/20 0.41
▸ IDO1 P14902 1/20 0.41
▸ NOTUM Q6P988 1/20 0.41
▸ TSHR P16473 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ SCN2A Q99250 1/20 0.40
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ HRH1 P35367 1/20 0.39
▸ HRH4 Q9H3N8 1/20 0.39
▸ RORB Q92753 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16127491 0.87 IKBKB (0.53) IKBKBBRD4MAOBMAPTCNR2
SCHEMBL4302188 0.78 TAAR1 (0.42) MAPTIDO1NOTUM
SCHEMBL22238791 0.77 CRHBP (0.39) MAPK1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL29656838 0.77 IKBKB (0.46) IKBKBBRD4MAOBMAPTCNR2
SCHEMBL17563223 0.76 SLC1A3 (0.50) IKBKBBRD4MAOBMAPTCNR2
SCHEMBL3560562 0.76 DHODH (0.40) —
SCHEMBL27277437 0.75 CYP1A2 (0.45) MAOBMAPTTDP1MAPK1CYP1A2
SCHEMBL3570521 0.75 CHRM1 (0.40) MAOBIDO1NOTUMTSHRNPC1
SCHEMBL29625567 0.75 MAOB (0.49) MAOBADORA1AKR1C3AKR1C2IDO1
SCHEMBL1865690 0.75 CSNK1E (0.43) CNR2AKR1C3AKR1C2TSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7858624-B2 Piperidine and morpholine renin inhibitors VITAE PHARMACEUTICALS, INC. (US) 2010-12-28 — — US disclosed
US-20090275581-A1 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2009-11-05 — — US disclosed
US-20090264432-A1 Piperidine and Morpholine Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2009-10-22 — — US disclosed
EP-2010488-A2 RENIN INHIBITORS Vitae Pharmaceuticals, Inc. (US) 2009-01-07 — — EP disclosed
WO-2007117560-A2 PIPERIDINE AND MORPHOLINE RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-10-18 — — WO disclosed
WO-2007117559-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-10-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275581-A1 RENIN INHIBITORS REN, ACE, SERPINB1 IKBKB 702/4885BRD4 2118/4885MAOB 668/4885
US-20090264432-A1 Piperidine and Morpholine Renin Inhibitors REN, ACE, PREP IKBKB 1722/4885BRD4 521/4885MAOB 378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback